Literature DB >> 19947643

New developments in the comprehension of the biotransformation and transport of insulin-enhancing vanadium compounds in the blood serum.

Daniele Sanna1, Giovanni Micera, Eugenio Garribba.   

Abstract

The possible biotransformations in the blood serum of four representative insulin-enhancing vanadium compounds, [VO(6-mepic)(2)], cis-[VO(pic)(2)(H(2)O)], [VO(acac)(2)], and [VO(dhp)(2)], where 6-mepic, pic, acac, and dhp indicate the deprotonated forms of 6-methylpicolinic and picolinic acids, acetylacetone, and 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone, were examined. In particular, the behavior of the quinary systems formed by the insulin-enhancing species, human serum apo-transferrin (hTf), human serum albumin (HSA), and lactate (lact) or citrate (citr) at physiological pH and conditions was studied. The results indicate that, besides the case in which the ligand is very weak like 6-mepic, the carrier can interact in some form with VO(2+) ion until its intake into the cell. In fact with stronger ligands like pic, acac, and dhp, VO(2+) is transported not only by transferrin but also as [VO(carrier)(2)] and as mixed species VO(2+)-hTF-carrier. There are two ways in which the undissociated form of a bis-chelated complex can interact with transferrin, one "specific" when the carrier possesses a carboxylate group and behaves like a synergistic anion, and another "non-specific" when an imidazole nitrogen of a histidine residue from hTf replaces an equatorially coordinated water molecule giving rise to a ternary species with cis-octahedral geometry and cis-VO(carrier)(2)(hTf) stoichiometry. It is found that also albumin can participate in the transport of an insulin-enhancing compound forming a mixed species cis-VO(carrier)(2)(HSA), when the carrier stabilizes in aqueous solution the cis-octahedral form, or the dinuclear compound (VO)(2)(d)HSA, when the carrier forms unstable complexes. These insights were confirmed through density functional theory (DFT) calculations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19947643     DOI: 10.1021/ic9017213

Source DB:  PubMed          Journal:  Inorg Chem        ISSN: 0020-1669            Impact factor:   5.165


  12 in total

1.  Application of DFT methods to the study of the coordination environment of the VO2+ ion in V proteins.

Authors:  Daniele Sanna; Vincent L Pecoraro; Giovanni Micera; Eugenio Garribba
Journal:  J Biol Inorg Chem       Date:  2012-04-15       Impact factor: 3.358

2.  Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model.

Authors:  I E León; J F Cadavid-Vargas; I Tiscornia; V Porro; S Castelli; P Katkar; A Desideri; M Bollati-Fogolin; S B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2015-09-24       Impact factor: 3.358

3.  The Structural Basis of Action of Vanadyl (VO2+) Chelates in Cells.

Authors:  Marvin W Makinen; Marzieh Salehitazangi
Journal:  Coord Chem Rev       Date:  2014-11-01       Impact factor: 22.315

4.  Binding of V(IV)O²⁺ to the Fe binding sites of human serum transferrin. A theoretical study.

Authors:  Gonçalo C Justino; Eugenio Garribba; João Costa Pessoa
Journal:  J Biol Inorg Chem       Date:  2013-10       Impact factor: 3.358

5.  A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.

Authors:  Daniele Sanna; Péter Buglyó; Giovanni Micera; Eugenio Garribba
Journal:  J Biol Inorg Chem       Date:  2010-03-26       Impact factor: 3.358

6.  Multiple and Variable Binding of Pharmacologically Active Bis(maltolato)oxidovanadium(IV) to Lysozyme.

Authors:  Giarita Ferraro; Maddalena Paolillo; Giuseppe Sciortino; Eugenio Garribba; Antonello Merlino
Journal:  Inorg Chem       Date:  2022-10-07       Impact factor: 5.436

7.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

8.  Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients.

Authors:  Gail R Willsky; Katherine Halvorsen; Michael E Godzala; Lai-Har Chi; Mathew J Most; Peter Kaszynski; Debbie C Crans; Allison B Goldfine; Paul J Kostyniak
Journal:  Metallomics       Date:  2013-11       Impact factor: 4.526

Review 9.  Vanadium: History, chemistry, interactions with α-amino acids and potential therapeutic applications.

Authors:  Edgar Del Carpio; Lino Hernández; Carlos Ciangherotti; Valentina Villalobos Coa; Lissette Jiménez; Vito Lubes; Giuseppe Lubes
Journal:  Coord Chem Rev       Date:  2018-06-21       Impact factor: 22.315

10.  ESI-MS Study of the Interaction of Potential Oxidovanadium(IV) Drugs and Amavadin with Model Proteins.

Authors:  Valeria Ugone; Daniele Sanna; Giuseppe Sciortino; Debbie C Crans; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-06-25       Impact factor: 5.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.